NECCHI, ANDREA
 Distribuzione geografica
Continente #
EU - Europa 662
NA - Nord America 413
AS - Asia 130
SA - Sud America 4
Totale 1.209
Nazione #
US - Stati Uniti d'America 410
DE - Germania 320
GB - Regno Unito 192
CN - Cina 58
SE - Svezia 47
IT - Italia 40
SG - Singapore 37
IE - Irlanda 16
FI - Finlandia 12
IN - India 11
KR - Corea 11
FR - Francia 8
BE - Belgio 7
UA - Ucraina 5
HK - Hong Kong 4
DK - Danimarca 3
JP - Giappone 3
NL - Olanda 3
AT - Austria 2
BR - Brasile 2
CA - Canada 2
GR - Grecia 2
TR - Turchia 2
VN - Vietnam 2
AR - Argentina 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
ES - Italia 1
IL - Israele 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
PL - Polonia 1
RU - Federazione Russa 1
Totale 1.209
Città #
Frankfurt am Main 298
Southend 158
Chandler 140
Seattle 31
Wilmington 28
Milan 26
Princeton 24
Ann Arbor 19
Fairfield 17
Dublin 16
Munich 15
Singapore 15
Phoenix 12
Falls Church 10
Nanjing 10
Des Moines 9
Ashburn 7
Beijing 7
Bengaluru 7
Brussels 7
Houston 6
Jinan 6
Woodbridge 6
New York 5
San Diego 5
Boardman 4
Changsha 4
Shenyang 4
Chicago 3
Eitensheim 3
Hong Kong 3
London 3
Redwood City 3
Tokyo 3
Amsterdam 2
Cambridge 2
Chengdu 2
Haikou 2
Hangzhou 2
Hanoi 2
Hebei 2
Hefei 2
Jiaxing 2
Kunming 2
Mumbai 2
Seoul 2
Toronto 2
Zhengzhou 2
Almere Stad 1
Andover 1
Athens 1
Bitonto 1
Brno 1
Buffalo 1
Central District 1
Cleveland 1
Concesio 1
Council Bluffs 1
Fremont 1
Fuzhou 1
Haifa 1
Helsinki 1
Huntington 1
Hyderabad 1
Kuala Lumpur 1
Los Angeles 1
Madrid 1
Mountain View 1
Oslo 1
Puebla City 1
Quito 1
Taiyuan 1
Thessaloníki 1
Tianjin 1
Vienna 1
Totale 969
Nome #
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma 134
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation 127
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma 125
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy 112
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer 108
Immunotherapy advances in uro-genital malignancies 97
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 97
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma : a systematic review and meta-analysis of patient outcomes 93
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes 87
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment 80
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer : an open label, single-group, phase 2 trial 75
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer 74
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees 48
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees 46
Totale 1.303
Categoria #
all - tutte 3.462
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.462


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202098 15 1 4 7 2 4 7 10 24 15 7 2
2020/202177 38 1 1 1 6 7 1 9 8 2 0 3
2021/2022147 3 1 3 2 10 12 6 5 7 17 17 64
2022/2023263 32 45 32 39 9 34 7 17 41 1 3 3
2023/2024360 3 6 5 7 30 3 59 51 24 52 58 62
2024/202529 29 0 0 0 0 0 0 0 0 0 0 0
Totale 1.303